News | Cardiac Resynchronization Therapy Devices (CRT) | April 29, 2019

Biotronik Launches Acticor DX and CRT-DX Devices in U.S.

New hybrid ICDs feature increased longevity, smooth BIOshape and simplified DF4 header configuration

Biotronik Launches Acticor DX and CRT-DX Devices in U.S.

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices. Electrophysiologists throughout the United States are now treating patients with the new implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).

When implanted with Biotronik's Plexa ProMRI S DX lead, the hybrid ICD Acticor systems offer dual-chamber diagnostics without the need for an atrial lead. Importantly, all three Acticor DX devices feature a new DF4 header configuration with a penta-polar electrode lead cable design that simplifies the implant procedure for physicians.

Larry Chinitz, M.D., and Lior Jankelson, M.D., Ph.D., New York, N.Y.; and Chafik Assal, M.D., Charleston, W.Va.; are among the first in the country to treat patients with Acticor.

"Smaller device systems with greater diagnostic capabilities and longer battery life improve how we treat patients," said George Thomas, M.D., New York, N.Y. "The new Acticor DX devices offer a simplified DF4 lead connection for the DX system. In my first cases, the slimmer, smoother device fit more easily in the pocket and substantially improved patient comfort post-op. These features bring clinical value and enhance patient quality of life."

Biotronik's unique DX technology enables the detection of silent atrial fibrillation; this helps prevent stroke, enhances diagnostic accuracy to improve clinical decision-making and allows for supraventricular tachycardia (SVT) discrimination to prevent unnecessary shocks. By reducing the number of leads, procedure times are faster and costs and complications are decreased.

The U.S. Food and Drug Administration (FDA) approved Acticor DX, Acticor CRT-DX Bipolar and Acticor CRT-DX in March, along with the Rivacor device family for the treatment of tachycardia and heart failure. Acticor and Rivacor are the smallest and slimmest cardiac rhythm management (CRM) devices approved for use in full-body, 3 Tesla (3T) magnetic resonance imaging (MRI) scans, according to the company. The new devices measure just 10 mm thin, with a smooth, rounded BIOshape that eases implantation and increases patient comfort. The devices have improved battery longevity — nearly 15 years for Rivacor VR-T, 13.5 years for Rivacor DR-T, 14 years for Acticor DX, and 11 years for both Rivacor CRT and Acticor CRT-DX. They are backed by extended device warranties.

Read the article "FDA Approves 3T Acticor and Rivacor Tachycardia Devices from Biotronik"

The ultraslim Acticor and Rivacor device systems feature MRI AutoDetect, Closed Loop Stimulation and Biotroink Home Monitoring. As a result, they provide more efficient MRI access, individualized physiological rate response and remote monitoring that is proven to reduce all-cause mortality in heart failure patients by more than 60 percent

For more information: www.biotronik.com

Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure ...

Home October 27, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...

Home March 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved ...

Home May 22, 2018
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

February 26, 2018 — The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain ...

Home February 26, 2018
Home
Subscribe Now